Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid

Simply Wall St.05-09

Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs. The agreement prevents Hetero from launching a generic FIRDAPSE product in the U.S. before...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2634416499?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-05-09 22:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2634416499","market":"sg","top_or_hot":-1,"title":"Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid","media":"Simply Wall St.","content":"<div>\n<p>Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs. The agreement prevents Hetero from launching a generic FIRDAPSE product in the U.S. before...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-firdapse-deal-extends-exclusivity-to-2035-and-shape\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Catalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCatalyst FIRDAPSE Deal Extends Exclusivity To 2035 And Shapes Angelini Bid\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-05-09 22:36 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-firdapse-deal-extends-exclusivity-to-2035-and-shape><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs. The agreement prevents Hetero from launching a generic FIRDAPSE product in the U.S. before...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-firdapse-deal-extends-exclusivity-to-2035-and-shape\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-firdapse-deal-extends-exclusivity-to-2035-and-shape","article_id":"2634416499","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cprx/catalyst-pharmaceuticals/news/catalyst-firdapse-deal-extends-exclusivity-to-2035-and-shape","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2634416499","pubTimestamp":1778337416,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs.\nThe agreement prevents Hetero from launching a generic FIRDAPSE product in the U.S. before January 2035.\nThe settlement secures extended U.S. market exclusivity for FIRDAPSE and removes a key legal overhang for Catalyst.\n\nCatalyst Pharmaceuticals focuses on treatments for rare neurological diseases, with FIRDAPSE as its lead commercial product. In that context, the settlement with...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","CPRX":"Catalyst Pharmaceutical Partners","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D"},"translate_title":"Catalyst FIRDAPSE交易将独家经营权延长至2035年并影响Angelini的出价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CPRX":0.9},"content_text":"Catalyst Pharmaceuticals (NasdaqCM:CPRX) has settled all pending FIRDAPSE patent litigation with Hetero Labs. The agreement prevents Hetero from launching a generic FIRDAPSE product in the U.S. before January 2035. The settlement secures extended U.S. market exclusivity for FIRDAPSE and removes a key legal overhang for Catalyst.  Catalyst Pharmaceuticals focuses on treatments for rare neurological diseases, with FIRDAPSE as its lead commercial product. In that context, the settlement with Hetero Labs matters because it directly addresses generic risk around the company’s core drug. For investors watching NasdaqCM:CPRX, the resolution gives clearer visibility on how long FIRDAPSE may remain the only approved version in the U.S. With the litigation now resolved, attention is likely to remain on how Catalyst and its future owner Angelini Pharma manage this extended exclusivity period. Key questions for readers include how the company prioritizes reinvestment in its pipeline, potential new indications, and any additional products that could diversify revenue beyond FIRDAPSE over time. Stay updated on the most important news stories for Catalyst Pharmaceuticals by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Catalyst Pharmaceuticals. NasdaqCM:CPRX Earnings & Revenue Growth as at May 2026 We've flagged 0 risks for Catalyst Pharmaceuticals. See which could impact your investment. The settlement with Hetero effectively locks in U.S. FIRDAPSE exclusivity until January 2035, which removes a key uncertainty around Catalyst’s largest product just as Angelini Pharma is preparing to acquire the company. For you as a shareholder, that combination matters because it ties a long-duration cash-flow asset to a cash takeover that has already been agreed at US$31.50 per share. The agreement also ends all remaining FIRDAPSE patent disputes, meaning Angelini is not stepping into open litigation risk on the core franchise. Compared with other rare-disease and neurology-focused groups such as BioMarin, UCB or Alexion within AstraZeneca, Catalyst now presents as a cleaner, single-asset anchored platform in the U.S., which can be attractive for a buyer looking to expand its rare-disease footprint. The trade off is that existing investors are now mainly exposed to deal-completion risk rather than to the long-run outcome of that extended exclusivity period. AdvertisementHow This Fits Into The Catalyst Pharmaceuticals Narrative  The settlement supports the existing narrative that FIRDAPSE provides a durable rare-disease revenue base, by clarifying that generic competition from Hetero is off the table in the U.S. until 2035 if it receives approval. It challenges earlier concerns in the narrative about near to medium term patent risk around FIRDAPSE, because this specific litigation path has now been closed out through settlements with multiple generic filers. The Angelini acquisition context, and the shift from an independent growth story to an agreed cash sale, is not fully reflected in the narrative’s focus on long-term earnings expansion and capital allocation by Catalyst as a standalone company.  Knowing what a company is worth starts with understanding its story.\nCheck out one of the top narratives in the Simply Wall St Community for Catalyst Pharmaceuticals to help decide what it's worth to you. The Risks and Rewards Investors Should Consider  ⚠️ The acquisition still depends on Catalyst stockholder approval, regulatory clearances and other conditions, so there is a risk the transaction with Angelini does not close on the expected timeline or on the current terms. ⚠️ The agreed US$31.50 per share cash price can limit further upside if no competing bids emerge, which may feel restrictive if you think the longer FIRDAPSE exclusivity could have supported a higher standalone valuation. 🎁 The settlement removes the immediate threat of Hetero launching a FIRDAPSE generic before 2035, which reduces legal overhang around Catalyst’s key product and provides clearer revenue visibility for the buyer. 🎁 Combining Catalyst’s rare-disease portfolio with Angelini’s broader brain-health focus and international reach could create product and geographic synergies that support the combined group’s positioning against peers like BioMarin and UCB.  What To Watch Going Forward From here, keep an eye on formal filings of the Hetero settlement with U.S. regulators, any commentary from Catalyst or Angelini about how FIRDAPSE exclusivity factors into the merger rationale, and updates on regulatory and antitrust review for the acquisition. It is also worth tracking whether any shareholder groups challenge the deal terms or whether alternative proposals surface before the stockholder vote, given the defined cash price and the now-clarified patent outlook for FIRDAPSE. To stay informed on how the latest news impacts the investment narrative for Catalyst Pharmaceuticals, visit the\ncommunity page for Catalyst Pharmaceuticals to follow the top community narratives.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2634416499","isCrawlerRequest":true}